{"schema_version":"1.0","type":"article","title":"26 家藥廠、89% 市場覆蓋：MFN 藥價協議真正落地到哪一層？","url":"https://drugnews.com.tw/articles/2026-09-17-mfn26-beone-policy-bargain.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-17-mfn26-beone-policy-bargain.md","lang":"zh-Hant","date":"2026-09-17","publish_at":"2026-09-17T08:00:00+08:00","updated_at":"2026-09-17","category":"商業分析系列","topic":"商業分析系列","tags":["MFN","Medicaid","GENEROUS","BeOne","Teva","藥價政策"],"summary":"白宮所稱 26 家與 89% 描述政策廣度，不等於各家公司條款、各州執行與逐藥價格已同步定案；BeOne 與 Teva 正好呈現成熟度差異。","key_points":[],"facts":[],"sections":["01｜先拆開三個問題：誰被列名、誰完成條款、誰真的開始請款？","02｜GENEROUS 不是患者拿到一張折價券，而是 Medicaid 淨價的州級機制","03｜最大的證據警訊：白宮寫「九項新協議」，Teva 卻仍寫「積極協商中」","04｜BeOne 為什麼仍值得當案例？因為它揭露的交換項目比較完整","05｜196 億美元與 290.975 公噸：供應鏈已被放進藥價談判桌","06｜26 家協議對公司價值的影響，要分五本帳，而不是只問「利多或利空」","07｜對中國創新藥與台灣產業，真正要追的是條款傳導，不是硬貼概念股","08｜接下來要等的，不是一個更大的 headline，而是四種可讀回證據"],"references":[],"images":[{"alt":"圖 1｜26 家與 89% 是政策廣度，不是條款成熟度","url":"https://drugnews.com.tw/assets/articles/mfn26-beone-policy-bargain/01_MFN%E4%BA%8C%E5%8D%81%E5%85%AD%E5%AE%B6%E8%88%87%E5%85%AB%E5%8D%81%E4%B9%9D%E7%99%BE%E5%88%86%E6%AF%94%E6%94%BF%E7%AD%96%E8%A6%86%E8%93%8B%E5%8F%8D%E5%B7%AE_typed_v1.png"},{"alt":"圖 2｜GENEROUS 從 CMS 框架走到州補充返利","url":"https://drugnews.com.tw/assets/articles/mfn26-beone-policy-bargain/02_GENEROUS%E5%B7%9E%E8%A3%9C%E5%85%85%E8%BF%94%E5%88%A9%E8%88%87%E8%87%AA%E9%A1%98%E5%8F%83%E8%88%87%E6%A9%9F%E5%88%B6_typed_v1.png"},{"alt":"圖 3｜白宮、BeOne、Teva 的協議成熟度不可混寫","url":"https://drugnews.com.tw/assets/articles/mfn26-beone-policy-bargain/03_%E7%99%BD%E5%AE%AEBeOne%E8%88%87Teva%E5%8D%94%E8%AD%B0%E6%88%90%E7%86%9F%E5%BA%A6%E5%B7%AE%E7%95%B0_typed_v1.png"},{"alt":"圖 4｜藥價、投資與 API 供應鏈是同一張交換帳","url":"https://drugnews.com.tw/assets/articles/mfn26-beone-policy-bargain/04_%E8%97%A5%E5%83%B9%E6%8A%95%E8%B3%87%E8%88%87API%E4%BE%9B%E6%87%89%E9%8F%88%E4%BA%A4%E6%8F%9B%E5%B8%B3_typed_v1.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/mfn26-beone-policy-bargain/01_MFN%E4%BA%8C%E5%8D%81%E5%85%AD%E5%AE%B6%E8%88%87%E5%85%AB%E5%8D%81%E4%B9%9D%E7%99%BE%E5%88%86%E6%AF%94%E6%94%BF%E7%AD%96%E8%A6%86%E8%93%8B%E5%8F%8D%E5%B7%AE_typed_v1.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-17）。26 家藥廠、89% 市場覆蓋：MFN 藥價協議真正落地到哪一層？。https://drugnews.com.tw/articles/2026-09-17-mfn26-beone-policy-bargain.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}